scholarly journals New onset severe right ventricular failure associated with COVID-19 in a young infant without previous heart disease

2020 ◽  
Vol 30 (9) ◽  
pp. 1346-1349 ◽  
Author(s):  
Moises Rodriguez-Gonzalez ◽  
Patricia Rodríguez-Campoy ◽  
Maria Sánchez-Códez ◽  
Irene Gutiérrez-Rosa ◽  
Ana Castellano-Martinez ◽  
...  

AbstractWe present our recent experience with a 6-month-old infant with a personal history of short bowel syndrome that presented with fever, cyanosis, and cardiogenic shock secondary to severe pulmonary hypertension and right ventricular failure without pulmonary thromboembolism. He did not present signs of toxin-mediated disease or Kawasaki disease. He was finally diagnosed with SARS-CoV-2 infection. If this presentation is confirmed in future research, the severe cardiovascular impairment in children with COVID-19 could be also attributable to the primary pulmonary infection, not only to a multisystem inflammatory syndrome but also in children without heart disease.

2010 ◽  
Vol 139 (5) ◽  
pp. 1197-1204.e1 ◽  
Author(s):  
Virginie Lambert ◽  
André Capderou ◽  
Emmanuel Le Bret ◽  
Catherine Rücker-Martin ◽  
Edith Deroubaix ◽  
...  

Author(s):  
S. Dalla Volta ◽  
R. Razzolini ◽  
L. Daliento ◽  
R. Chioin ◽  
N. John ◽  
...  

2017 ◽  
Vol 65 (08) ◽  
pp. 639-648 ◽  
Author(s):  
Rüdiger Lange ◽  
Melchior Burri

AbstractSurgical repair of the tricuspid valve is a milestone in the medical history of patients with Ebstein's anomaly. The timely alleviation of the insufficiency has an important impact on the prognosis. In this review, we describe features of the disease relevant to surgical correction and the evolution of surgical techniques over six decades. We compare the results of different repair and replacement techniques. Additionally, we discuss concomitant antiarrhythmic surgery and bailout strategies for postoperative right ventricular failure. Finally, we review the surgical options in symptomatic neonates with Ebstein's disease.


2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Jacqueline T. DesJardin ◽  
Lucas S. Zier

Pulmonary hypertension (PH) is a known consequence of sickle cell disease (SCD) and is associated with increased mortality and more frequent episodes of acute chest syndrome (ACS). Pulmonary pressures are known to increase during ACS, and right ventricular (RV) failure has been described as a significant cause of mortality in this condition. Management of ACS includes exchange transfusion, pain control, and prevention of hypovolemia and hypoxemia. However, in patients with a history of precapillary PH in whom ACS is complicated by persistent RV failure and cardiogenic shock, RV afterload reduction with pulmonary vasodilators may be an effective treatment strategy. Here, we present a case of a young man with SCD-associated PH and ACS who was successfully managed with inhaled and oral pulmonary vasodilators in the setting of persistent elevations in pulmonary vascular resistance leading to acute RV failure and cardiogenic shock.


Sign in / Sign up

Export Citation Format

Share Document